Distalmotion receives FDA clearance for additional gynecology indications
The DEXTER Robotic Surgery System is cleared for sacrocolpopexy, sacrocervicopexy, sacrohysteropexy, and endometriosis resection.
See the latest news and media coverage for Distalmotion. We track all announcements, press releases, and industry mentions in real time, all in one place.
Manufacturer of robotic surgery systems
distalmotion.comLast updated
In short: Distalmotion accelerated the U.S. commercial rollout of its DEXTER robotic system, securing $150 million in funding and multiple FDA clearances.
The DEXTER Robotic Surgery System is cleared for sacrocolpopexy, sacrocervicopexy, sacrohysteropexy, and endometriosis resection.
It follows SPARO trial completion. Clearance adds fourth US indication, second in gynecology, aiding outpatient procedures. CEO highlights outpatient robotics evolution.
The study documents the use of DEXTER® in robot-assisted partial nephrectomies with solid results in safety and performance.
The case occurs at Klinikum Landkreis Erding days after installation, integrating into routine workflows. Early application builds sustainable robotic programs.
Distalmotion announced today that it received FDA 510(k) clearance for its Dexter surgical robot in a range of gynecology ...
The company is seeking clearance in additional gynecological indications to support outpatient use of its surgical robot.
Distalmotion’s Dexter surgical robotics system challenges the clinical and economic barriers that limit ambulatory surgical centers’ access to innovation.
Distalmotion SA recently secured a strategic investment from Johnson & Johnson for its robotic-assisted surgical system Dexter, amid an increase in demand from ambulatory surgery...
Track Distalmotion and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Distalmotion and other trending companies.